Home > Boards > US Listed > Biotechs > Seattle Genetics (SGEN)

Delving Into Seattle Genetics’s Upcoming Readout http://marketexclusive.com/delving-seattle-geneti

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
trendmkr Member Profile
 
Followed By 12
Posts 911
Boards Moderated 0
Alias Born 05/29/15
160x600 placeholder
Seagen to Present at the Cowen 41st Annual Healthcare Conference Business Wire - 2/24/2021 8:00:00 AM
Astellas and Seagen submit two approval requests for bladder cancer therapy Seeking Alpha - 2/18/2021 4:12:28 PM
Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfo... PR Newswire (US) - 2/18/2021 8:00:00 AM
Seagen & Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfort... Business Wire - 2/18/2021 8:00:00 AM
Schedule 13g Edgar (US Regulatory) - 2/16/2021 4:23:42 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 12:31:14 PM
Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in ... PR Newswire (US) - 2/12/2021 2:15:00 PM
Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with P... PR Newswire (US) - 2/12/2021 2:15:00 PM
Seagen & Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Pa... Business Wire - 2/12/2021 2:15:00 PM
Seagen & Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Pre... Business Wire - 2/12/2021 2:15:00 PM
Annual Report (10-k) Edgar (US Regulatory) - 2/12/2021 7:53:17 AM
Seagen’s Tukysa wins European approval for breast cancer Seeking Alpha - 2/12/2021 7:45:48 AM
European Commission Approves Seagen’s TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastati... Business Wire - 2/12/2021 6:45:00 AM
European Commission Approves Seagen’s TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastati... Business Wire - 2/12/2021 6:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/11/2021 4:08:15 PM
Seattle Genetics EPS beats by $0.04, beats on revenue Seeking Alpha - 2/11/2021 4:06:40 PM
Seagen Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire - 2/11/2021 4:02:00 PM
Seagen Q4 2020 Earnings Preview Seeking Alpha - 2/10/2021 5:35:10 PM
Genmab and Seagen submit tisotumab vedotin BLA to the FDA Seeking Alpha - 2/10/2021 4:26:56 PM
Seagen & Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metasta... Business Wire - 2/10/2021 4:05:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/10/2021 11:58:40 AM
Ocugen, CRH Medical leads healthcare gainers; ERYTECH Pharma, Panbela Therapeutics among major losers Seeking Alpha - 2/8/2021 11:01:06 AM
Schedule 13g Edgar (US Regulatory) - 2/4/2021 11:43:19 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/1/2021 8:18:12 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences